• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    7/10/23 12:34:28 PM ET
    $AAN
    $ADN
    $ALPP
    $ARAV
    Diversified Commercial Services
    Consumer Discretionary
    Industrial Machinery/Components
    Miscellaneous
    Get the next $AAN alert in real time by email

    Gainers

    • Mobilicom Limited (NASDAQ:MOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the U.S. Department of Defense.
    • Nanobiotix S.A. (NASDAQ:NBTX) shares jumped 45.5% to $7.32 after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) shares rose 36% to $0.1565 after gaining over 38% on Friday.
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) gained 34.8% to $0.4934 after the company announced it has executed an Asset Purchase Agreement with GBB Drink Lab to acquire all operating assets including the "Safety Shot" rapid alcohol detox drink.
    • NanoString Technologies, Inc. (NASDAQ:NSTG) shares gained 32.4% to $4.90 after the company said it expects second-quarter revenue to be over $44 million, above the upper end of its guidance range and the $41 million consensus estimate. The company also reiterated FY23 revenue guidance above the consensus estimate.
    • Gorilla Technology Group Inc. (NASDAQ:GRRR) gained 30.8% to $6.15. Gorilla Technology shares jumped 125% on Friday after the company signed a $270 million contract with the Government of Egypt to implement a Smart Government Security Convergence solution.
    • Shineco, Inc. (NASDAQ:SISI) gained 28.5% to $0.4165 after the company announced its subsidiary received marketing and distribution approval for its Cardiac 5-Minute Test from the Jiangsu Bureau of China's National Medical Products Administration.
    • Alpine 4 Holdings, Inc. (NASDAQ:ALPP) shares rose 22% to $2.05 after the company said its subsidiary, Vayu Aerospace Corporation, received its first $5.25m purchase order from its $100 million supply agreement with U.S. Government contractor, All American Contracting, Inc.
    • Novavax, Inc. (NASDAQ:NVAX) gained 21.2% to $8.77. The European Commission recently approved Novavax’s Nuvaxovid (NVX-CoV2373), following a positive opinion for a full authorization from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
    • Marker Therapeutics, Inc. (NASDAQ:MRKR) rose 19.8% to $5.20 after the company announced the European Medicines Agency granted MT-401 an Orphan Drug Designation.
    • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) gained 19% to $1.44.
    • Icahn Enterprises L.P. (NASDAQ:IEP) gained 17.8% to $34.02 after Carl Icahn amended loan agreements, disconnecting his personal loans from the share price, increasing his collateral and establishing a plan to repay the loans within three years. This was an issue raised in Hindenburg Research's short report on the stock issued in May.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) gained 17.5% to $8.51 after the company announced regulatory, clinical updates for TIL therapy in advanced non-small cell lung cancer.
    • SOS Limited (NYSE:SOS) gained 17.4% to $5.31.
    • Aravive, Inc. (NASDAQ:ARAV) climbed 17.4% to $1.55. Cantor Fitzgerald reiterated Aravive with an Overweight and maintained $18 price target.
    • Advent Technologies Holdings, Inc. (NASDAQ:ADN) gained 17.4% to $0.7399.
    • Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) jumped 17% to $3.03.
    • Stronghold Digital Mining, Inc. (NASDAQ:SDIG) gained 16.1% to $8.16.
    • Helen of Troy Limited (NASDAQ:HELE) rose 15.7% to $130.26 after the company reported better-than-expected first-quarter financial results and issued guidance.
    • TMC the metals company Inc. (NASDAQ:TMC) jumped 15.3% to $2.9150 after ThinkEquity initiated coverage on the stock with a Buy rating and announced a $6 price target.
    • fuboTV Inc. (NYSE:FUBO) gained 14.2% to $2.48.
    • Groupon, Inc. (NASDAQ:GRPN) jumped 13.8% to $6.95.
    • Siyata Mobile Inc. (NASDAQ:SYTA) shares climbed 12.9% to $0.07 after gaining around 12% on Friday.
    • Lyft, Inc. (NASDAQ:LYFT) rose 11.2% to $11.26.
    • Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) shares gained 7.6% to $4.7450. Black Diamond Therapeutics Director Rajeev Shah purchased 935,850 shares at an average price of $5.00 per share.

    Losers

    • Tivic Health Systems, Inc. (NASDAQ:TIVC) shares fell 41.4% to $0.0650 after the company priced public offering of 32.5 million shares at $0.055 per share.
    • Neonode Inc. (NASDAQ:NEON) fell 33.8% to $4.85 after dropping over 8% on Friday.
    • ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares dropped 19.7% to $2.81. The company announced plans to voluntarily delist from the Toronto Stock Exchange.
    • Xcel Brands, Inc. (NASDAQ:XELB) dipped 19.4% to $1.16.
    • Nocera, Inc. (NASDAQ:NCRA) dropped 18.4% to $1.6480.
    • Presto Automation Inc. (NASDAQ:PRST) fell 18.1% to $3.49. Rajat Suri, 10% owner at Presto Automation, reported a large insider sell on July 6.
    • Tattooed Chef, Inc. (NASDAQ:TTCF) fell 16.4% to $0.2175.
    • Trinity Place Holdings Inc. (NYSE:TPHS) dropped 14.4% to $0.5481.
    • The Aaron's Company, Inc. (NYSE:AAN) fell 12.2% to $13.41 after Loop Capital downgraded the stock from Buy to Hold.
    • FOXO Technologies Inc. (NYSE:FOXO) dropped 12.2% to $0.18.
    • Metalpha Technology Holding Limited (NASDAQ:MATH) declined 11.8% to $1.27.
    • Shengfeng Development Limited (NASDAQ:SFWL) fell 11.3% to $8.97.
    • FMC Corporation (NYSE:FMC) dropped 11.3% to $92.42 after the company issued weak revenue guidance.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) fell 10.5% to $3.8899. Biodexa Ltd, subsidiary of Biodexa Pharmaceuticals, has completed the enrolment and treatment of nine pediatric patients in the ongoing Phase 1 study of MTX-110 in newly diagnosed diffuse midline gliomas.
    • SunCar Technology Group Inc. (NASDAQ:SDA) dropped 9.8% to $20.05.
    • MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) declined 9.7% to $1.0470.
    • VOXX International Corporation (NASDAQ:VOXX) fell 8.8% to $11.53.
    • 22nd Century Group, Inc. (NASDAQ:XXII) fell 8.5% to $2.45.
    • Femasys Inc. (NASDAQ:FEMY) fell 7% to $0.4785.

    Now Read This: This Analyst With 83% Accuracy Rate Sees Around 7% Upside In Alphabet - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

    Get the next $AAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAN
    $ADN
    $ALPP
    $ARAV

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    FuboTV Inc.
    $FUBO
    2/5/2026$3.00Neutral → Buy
    Seaport Research Partners
    Lyft Inc.
    $LYFT
    12/19/2025$16.00Neutral → Underperform
    Wedbush
    Gorilla Technology Group Inc.
    $GRRR
    12/11/2025$31.00Overweight
    Cantor Fitzgerald
    FMC Corporation
    $FMC
    12/9/2025$13.00Equal Weight → Underweight
    Barclays
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Lyft Inc.
    $LYFT
    12/3/2025$20.00Sell → Neutral
    Arete
    More analyst ratings

    $AAN
    $ADN
    $ALPP
    $ARAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Eugene bought $48,800 worth of shares (2,000 units at $24.40), increasing direct ownership by 19% to 12,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/6/26 7:28:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Barry Michael F bought $249,938 worth of shares (18,072 units at $13.83), increasing direct ownership by 1,157% to 19,634 units (SEC Form 4)

    4 - FMC CORP (0000037785) (Issuer)

    3/5/26 12:11:06 PM ET
    $FMC
    Major Chemicals
    Industrials

    Director Williams Eugene bought $92,420 worth of shares (4,000 units at $23.11), increasing direct ownership by 63% to 10,397 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    3/4/26 6:08:32 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ADN
    $ALPP
    $ARAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAN
    $ADN
    $ALPP
    $ARAV
    SEC Filings

    View All

    SEC Form 6-K filed by Mobilicom Limited

    6-K - Mobilicom Ltd (0001898643) (Filer)

    3/19/26 7:48:56 AM ET
    $MOB
    Aerospace
    Industrials

    SEC Form 10-K filed by Marker Therapeutics Inc.

    10-K - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/18/26 5:26:35 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs

    6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    3/18/26 5:11:41 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ADN
    $ALPP
    $ARAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chandan Jayesh

    3 - Gorilla Technology Group Inc. (0001903145) (Issuer)

    3/18/26 6:03:22 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Bower Bruce

    3 - Gorilla Technology Group Inc. (0001903145) (Issuer)

    3/18/26 6:03:07 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Sennhauser Thomas

    3 - Gorilla Technology Group Inc. (0001903145) (Issuer)

    3/18/26 6:02:51 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $AAN
    $ADN
    $ALPP
    $ARAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mobilicom's Drone and Robotics Solutions Included in FCC's First Batch of Trusted Drones as Determined by U.S. Department of War

    Mobilicom is one of only four companies to be exempted from import restrictions under the Covered List and the only company to have multiple products exempted Mobilicom is expanding its production capacity and expects to manufacture its cybersecure mission-critical systems in the U.S. by the end of 2026 Palo Alto, California, March 19, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced that its cybersecurity, hardware, and software solutions have been included in the Federal Communications Commission's (FCC) first batch of "Trusted Drones" as det

    3/19/26 7:47:00 AM ET
    $MOB
    Aerospace
    Industrials

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADR Ratio Change

    March 18, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026. Pursuant to the Ratio Change, ADR holders will be required on a

    3/18/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ADN
    $ALPP
    $ARAV
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    $AAN
    $ADN
    $ALPP
    $ARAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    fuboTV upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded fuboTV from Neutral to Buy and set a new price target of $3.00

    2/5/26 6:51:39 AM ET
    $FUBO
    Movies/Entertainment
    Consumer Discretionary

    $AAN
    $ADN
    $ALPP
    $ARAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/6/24 2:12:18 PM ET
    $GRPN
    Advertising
    Consumer Discretionary

    $AAN
    $ADN
    $ALPP
    $ARAV
    Financials

    Live finance-specific insights

    View All

    Mobilicom to Report Full Year 2025 Financial and Operating Results on March 23, 2026

    Palo Alto, California, March 16, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (NASDAQ:MOB, MOBBW), MOBBW) ("Mobilicom" or the "Company"), a provider of cybersecurity and robust solutions for drones and robotics, today announced that it will issue a press release with its financial and operational results for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Monday, March 23, 2026. The Company will also discuss its results and other corporate developments, followed by a Q&A session, on a conference call at 4:30 p.m. EST the same day. Investors are invited to email questions to the Company in advance to: [email protected]. Conference call & webcast info: Monda

    3/16/26 8:00:00 AM ET
    $MOB
    Aerospace
    Industrials

    Groupon Reports Fourth Quarter and Fiscal Year 2025 Results

    North America Q4 Local Revenue +4% and Local Billings +9%North America 2025 Local Revenue +5% and Local Billings +14%Positive Trailing twelve month operating cash flow from continuing operations of $64.5 million and Free Cash Flow of $49.9 millionChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced its financial results for the quarter and year ended December 31, 2025 and provided details on its recent operating progress. The Company filed its Form 10-K with the Securities and Exchange Commission and posted earnings commentary including an updated presentation on its investor relations website (investor.groupon.com)."Our 2025 results represent a

    3/10/26 4:15:00 PM ET
    $GRPN
    Advertising
    Consumer Discretionary

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care